Boost.ai Named as a Challenger in 2023 Gartner® Magic Quadrant™ for Enterprise Conversational AI Platforms
Boost.ai, a leading conversational AI platform, today announced it has been recognized as a Challenger by Gartner in their 2023 Magic Quadrant for Enterprise Conversational AI Platforms. For the second consecutive year, Boost.ai has been recognized in this Magic Quadrant by Gartner for its Ability to Execute and Completeness of Vision. We believe being recognized as a Challenger reinforces the company’s strength and leadership within the conversational AI space, as it continues to expand its technology and support a growing roster of clients across the globe.
The report states that “Gartner defines the enterprise conversational AI platform market as the market for software platforms used to build, orchestrate, and maintain multiple use cases of modalities of conversational automation.” As expectations for quality customer service continue to rise globally, Boost.ai has refined its technology, deploying industry-leading virtual agents that scale to meet the requirements of enterprise organizations. Boost.ai’s solution is powered by conversational AI, and the platform allows customers to scale up individually to thousands of industry-specific intents, enabling these businesses to effectively manage a very broad scope of customer queries in a matter of weeks in virtually any industry. With consistent 90% resolution rates, the solution facilitates immediate responses with accuracy, while its no-code conversation builder and AI trainer program allow customers to self-service their virtual agents and easily deploy service flows in response to customer feedback.
“Customer experience and digital transformation continue to be a priority, and I’m proud to say we have executed on this priority at Boost.ai. Over the last year, we’ve set customers up for success with our easily adaptable and scalable technology, and have solidified ourselves as world leaders in delivering the best possible customer experience for clients,” said Jerry Haywood, CEO of Boost.ai. “From my perspective, our placement in the 2023 Gartner Magic Quadrant is a testament to the work our team has done to perfect our solution and expand our existing offers based on new trends and technology.”
We believe this latest Magic Quadrant report encapsulates a strong previous year for Boost.ai, in which the company announced multiple customer wins and partnerships in the US and UK including Aspire Insurance, Metrobank, CallMiner, and Clarasys. The company also appointed Jerry Haywood as the new CEO, bringing 20 years of enterprise technology experience. With a conversational AI platform that delivers unlimited scalability as its central offering, Boost.ai is now leveraging its technology to tackle a new AI frontier: large language models (LLMs). Boost.ai combines the generative capabilities of LLMs like GPT-3, with company data to optimize their virtual agents for improved accuracy and brand alignment. As these models continue to develop, Boost.ai is working to ensure the technology can be properly integrated to offer the most advanced enterprise solution possible for both chat and voice.
"It’s an exciting time to be in the conversational AI space as the technology has taken another leap forward with the recent advancement of powerful LLMs. We think Future Gartner Magic Quadrant reports in this category could very well be defined by how well providers respond to this trend. We’re confident that we’re integrating the tech in a way that increases efficiency and performance, but most importantly is brand safe for our customers," said Lars Ropeid Selsås, Founder of Boost.ai. “I'm excited to see the massive amount of improvement our team and solution made in just one year, and now we can set our sights on solidifying our position in the market even further."
Boost.ai continues its upward global trajectory within the Enterprise Conversational AI market. The Boost.ai platform will focus on continuing to innovate and stay at the forefront of helping enterprise organizations to deliver exceptional customer experiences.
To learn more about how Boost.ai is empowering customers like DNB and Aspire Insurance using conversational AI, please visit: https://www.boost.ai/.
Gartner Disclaimer:
GARTNER is a registered trademark and service mark of Gartner Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005516/en/
Contact information
Jon Burch
Boost.ai@resonancecrowd.com
+44 208 819 3170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom